Pfizer is a much bigger company with numerous meds on the market and others in the pipeline.
Moderna has no med that has been approved for distribution, yet. They do have quite a few programs in clinical trials and a total of 20 developmental candidates. If those pan out, Moderna will do very well.
Earnings per share is a big deal and so is price/earnings ratio:
Pfizer has EPS of $1.54 and a PE of 23.75
Moderna has EPS of $(1.64) and has no PE, because, as most startups, it was losing money.
Shares outstanding, cash flow are considerations and so is future expectations and guidance.
Stock price is pretty meaningless at any moment or even period of time.
As Benjamin Graham, the famed value investor said: “In the short-term, the stock market is a voting machine; in the long-term, the market is a weighting machine.”
Moderna may nor not be successful with its initial product. Too early to make that call.
Some investors think that Moderna will be successful and will pay to own the stock. Moderna got a big cash boost from the U.S. government too, to develop a vaccine for Covid-19. That helps a lot.
Many factors contribute to stock price.
The share price is not relevant to the value of the stock. Though Moderna looks more expensive, with a market capital of $38 billion, it is actually far less valuable than Pfizer, which is valued at $204 billion and pays a 4% dividend annually. Pfizer had revenue last year of $52 billion while Moderna brought in $60 million which means Pfizer made 865 times more money. Pfizer has a P/E ratio of 23 while Moderna is losing money and a P/E cannot even be calculated at this time.
Pfizer has 5.56 billion outstanding shares while Moderna has 396 million. If Pfizer had the same 396 million outstanding shares…
Is Moderna stock just as good as Pfizer?
Both companies have been leaders in the fight against the coronavirus, but only one of their stocks is undervalued today.
Mentioned: Moderna Inc (MRNA) , BioNTech SE (BNTX) , Pfizer Inc (PFE)
Moderna and Pfizer became household names during the past two years, as they (along with BioNTech BNTX) brought COVID-19 vaccinations to market in record time. Today, both companies are working to add an omicron- based component to their mRNA booster shots.
Given their ongoing role in the fight against COVID-19,
this month’s stock-versus-stock feature looks at which is the better stock to buy now based on Morningstar’s proprietary metrics. Is it time to buy Moderna stock? Or is it time to buy Pfizer stock?
As part of this feature, we’re providing free access to a portion of the Morningstar Analyst Reports for both companies for a few weeks. By using the Analyst Reports for Moderna stock and Pfizer stock, an investor can dig
into some of Morningstar’s proprietary metrics more deeply and find out what our analysts have to say about each company’s business strategy. Investors will find that Moderna and Pfizer are very different companies.
Investors also have access to similar metrics about close competitors and the bull and bear cases for both stocks. Just click through the links below to access the complete reports for each stock.
Here’s how Moderna and Pfizer scored on some key investment metrics as of July 13, 2022:
Moderna Stock MRNA
Price/Fair Value: 0.74
Morningstar Uncertainty Rating: Very High
Morningstar Economic Moat Rating: None-Morningstar Capital Allocation Rating: Standard
Pfizer Stock PFE
Price/Fair Value: 1.08
Morningstar Uncertainty Rating: Medium
Morningstar Economic Moat Rating: Wide
Morningstar Capital Allocation Rating: Standard
At the end of the day, the “winner” of any stock-versus- stock comparison from Morningstar’s perspective is the stock that’s trading at the largest discount to our fair value estimate after being adjusted for uncertainty. The Morningstar Rating for stocks encapsulates just that.
Stocks rated 4 and 5 stars are undervalued after being adjusted for uncertainty, stocks rated 3 stars are fairly valued, and stocks rated 1 or 2 stars are overvalued after being adjusted for uncertainty.
Moderna stock earns a 4-star rating as of this writing, while Pfizer stock earns a 3-star rating. Moderna is the better stock to buy today from Morningstar’s perspective.
Moderna (MRNA) stock price prediction 2025
Moderna Inc (MRNA) Stock Price Prediction, Stock Forecast for next months and years
|November 2024||Open: 298.429||Change: 2.73 % ▲|
|December 2024||Open: 308.959||Change: – 0.95 %▼|
Moderna Inc Stock Price Forecast for 2025
|January 2025||Open: 306.000 C hange:||Change: 1.14 % ▲|
Moderna Stock Price Forecast 2023-2024
Moderna price started in 2023 at $179.62. Today, Moderna traded at $196.76, so the price increased by 10% from the beginning of the year. The forecasted Moderna price at the end of 2023 is $348 – and the year to year change +94%. The rise from today to year-end:
+77%. In the middle of 2023, we expect to see $240 per 1 Moderna. In the first half of 2024, the Moderna price will climb to $441; in the second half, the price would add
$56 and close the year at $497, which is +153% to the current price.
The short-term forecast: Thursday, Jan 26 – $197 Friday, Jan 27 – $197 Monday, Jan 30 – $198 Tuesday, Jan 31 – $198 Wednesday, Feb 1 – $199 Thursday, Feb 2 – $199 February 15 – $203 March 15 – $210
April 15 – $219 May 15 – $227
June 15 – $236 July 15 – $249
Moderna Stock Forecast 2025-2029
These five years would bring a significant increase: Moderna price would move from $497 to $1,054, which is up 112%. Moderna will start 2025 at $497, then soar to
$586 within the first six months of the year and finish 2025 at $599. That means +204% from today.
Stocks so low compared to Moderna
Moderna’s (MRNA -0.09%) stock is in poor shape. So far this year, it’s
Down more than 44% and its valuation multiples are slumping. On the Bright side, people can buy the shares far more cheaply right now than they
Could at any point in the last few years.
- Vaccine-stock mania is over
The most obvious reason Moderna’s stock is so cheap is that the market (and public)
Have moved beyond buying shares of heavily hyped vaccine stocks. Biotechs
Like Novavax and BioNTech saw their values absolutely explode while they were Actively
working on developing some of the world’s first coronavirus shots, but since
Roughly mid-2021 investors are cooling to prior winners. Jab revenue is likely to start falling ssoo
A collapsing hype cycle isn’t always enough to drive a high-flying company’s
Valuation down if it’s still growing and increasing its business – unless it’s known that
Those returns will decrease in the near future. And that’s exactly Moderna’s situation.
- Nothing else in the pipeline is ready for prime time
Falling future revenue from coronavirus vaccines wouldn’t be so troublesome if
Moderna had pipeline programs approaching maturity and potentially bearing
Revenue. Once again, the company’s investors are out of luck.
Moderna has a small handful of programs in phase 3 clinical trials, including a
Respiratory syncytial virus (RSV) vaccine and a cytomegalovirus (CMV) vaccine. But
Most members of the public are wholly unfamiliar with both of those viruses and the
Diseases they cause, so there’s no hope of restarting the hype train. Plus, according
To a report by Fortune Business Insights, the global market for RSV medicines will only be worth around $4 billion by 2027.
What is Moderna stock ticker ?
A stock ticker is a report of the price of certain securities, updated continuously throughout the trading session by the various stock market exchanges. A “tick” is any change in the price of the security, whether that movement is up or down.
What is the target price for mrna?
Stock Price Target
Average. $229.93 Current Price. $196.94
What is future of mRNA stock?
The 14 analysts offering 12-month price forecasts for Moderna Inc have a median target of 213.50, with a high estimate of 506.00 and a low estimate of 102.00
Who are the major stockholders in mRNA?
The top shareholders of Moderna are Robert S. Langer, Stéphane Bancel, Noubar B. Afeyan, Baillie Gifford & Company, and Flagship Pioneering Inc. “Insider” refers to people in senior management positions and members of the board of directors, as well as people or entities that own more than 10% of the company’s stock.
What is the Moderna price to earning ratio?
The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used
valuation measure. Moderna PE ratio as of January 23, 2023 is 7.13.